Literature DB >> 22284441

Longitudinal progression trajectory of GFR among patients with CKD.

Liang Li1, Brad C Astor, Julia Lewis, Bo Hu, Lawrence J Appel, Michael S Lipkowitz, Robert D Toto, Xuelei Wang, Jackson T Wright, Tom H Greene.   

Abstract

BACKGROUND: The traditional paradigm of glomerular filtration rate (GFR) progression in patients with chronic kidney disease (CKD) is a steady nearly linear decline over time. We describe individual GFR progression trajectories over 12 years of follow-up in participants in the African American Study of Kidney Disease and Hypertension (AASK). STUDY
DESIGN: Longitudinal observational study. SETTING & PARTICIPANTS: 846 AASK patients with at least 3 years of follow-up and 8 GFR estimates. MEASUREMENTS: Longitudinal GFR estimates from creatinine-based equations. PREDICTORS: Patient demographic and clinical features. OUTCOMES: Probability of a nonlinear trajectory and probability of a period of nonprogression calculated for each patient from a Bayesian model of individual estimated GFR (eGFR) trajectories.
RESULTS: 352 (41.6%) patients showed a > 0.9 probability of having either a nonlinear trajectory or a prolonged nonprogression period; in 559 (66.1%), the probability was > 0.5. Baseline eGFR > 40 mL/min/1.73 m2 and urine protein-creatinine ratio < 0.22 g/g were associated with a higher likelihood of a nonprogression period. 74 patients (8.7%) had both a substantial period of stable or increasing eGFR and a substantial period of rapid eGFR decrease. LIMITATIONS: Clinical trial population; absence of direct GFR measurements.
CONCLUSIONS: In contrast to the traditional paradigm of steady GFR progression over time, many patients with CKD have a nonlinear GFR trajectory or a prolonged period of nonprogression. These findings highlight the possibility that stable kidney disease progression can accelerate and, conversely, provide hope that CKD need not be relentlessly progressive. These results should encourage researchers to identify time-dependent factors associated with periods of nonprogression and other desirable trajectories. Copyright Â
© 2012 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22284441      PMCID: PMC3312980          DOI: 10.1053/j.ajkd.2011.12.009

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  13 in total

1.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.

Authors: 
Journal:  Am J Kidney Dis       Date:  2002-02       Impact factor: 8.860

2.  Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.

Authors:  E J Lewis; L G Hunsicker; W R Clarke; T Berl; M A Pohl; J B Lewis; E Ritz; R C Atkins; R Rohde; I Raz
Journal:  N Engl J Med       Date:  2001-09-20       Impact factor: 91.245

3.  Longitudinal studies on the rate of decline in renal function with age.

Authors:  R D Lindeman; J Tobin; N W Shock
Journal:  J Am Geriatr Soc       Date:  1985-04       Impact factor: 5.562

4.  A simple method of estimating progression of chronic renal failure.

Authors:  W E Mitch; M Walser; G A Buffington; J Lemann
Journal:  Lancet       Date:  1976-12-18       Impact factor: 79.321

5.  Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.

Authors:  Jackson T Wright; George Bakris; Tom Greene; Larry Y Agodoa; Lawrence J Appel; Jeanne Charleston; DeAnna Cheek; Janice G Douglas-Baltimore; Jennifer Gassman; Richard Glassock; Lee Hebert; Kenneth Jamerson; Julia Lewis; Robert A Phillips; Robert D Toto; John P Middleton; Stephen G Rostand
Journal:  JAMA       Date:  2002-11-20       Impact factor: 56.272

6.  Comparison of cross-sectional renal function measurements in African Americans with hypertensive nephrosclerosis and of primary formulas to estimate glomerular filtration rate.

Authors:  J Lewis; L Agodoa; D Cheek; T Greene; J Middleton; D O'Connor; A Ojo; R Phillips; M Sika; J Wright
Journal:  Am J Kidney Dis       Date:  2001-10       Impact factor: 8.860

7.  Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.

Authors:  B M Brenner; M E Cooper; D de Zeeuw; W F Keane; W E Mitch; H H Parving; G Remuzzi; S M Snapinn; Z Zhang; S Shahinfar
Journal:  N Engl J Med       Date:  2001-09-20       Impact factor: 91.245

8.  Baseline predictors of renal disease progression in the African American Study of Hypertension and Kidney Disease.

Authors:  Keith C Norris; Tom Greene; Joel Kopple; Janice Lea; Julia Lewis; Mike Lipkowitz; Pete Miller; Annie Richardson; Stephen Rostand; Xuelei Wang; Lawrence J Appel
Journal:  J Am Soc Nephrol       Date:  2006-09-07       Impact factor: 10.121

9.  Design and statistical aspects of the African American Study of Kidney Disease and Hypertension (AASK).

Authors:  Jennifer J Gassman; Tom Greene; Jackson T Wright; Lawrence Agodoa; George Bakris; Gerald J Beck; Janice Douglas; Ken Jamerson; Julia Lewis; Michael Kutner; Otelio S Randall; Shin-Ru Wang
Journal:  J Am Soc Nephrol       Date:  2003-07       Impact factor: 10.121

10.  The rationale and design of the AASK cohort study.

Authors:  Lawrence J Appel; John Middleton; Edgar R Miller; Michael Lipkowitz; Keith Norris; Lawrence Y Agodoa; George Bakris; Janice G Douglas; Jeanne Charleston; Jennifer Gassman; Tom Greene; Kenneth Jamerson; John W Kusek; Julia A Lewis; Robert A Phillips; Stephen G Rostand; Jackson T Wright
Journal:  J Am Soc Nephrol       Date:  2003-07       Impact factor: 10.121

View more
  125 in total

1.  Arteriovenous fistula as a nephroprotective intervention in advanced CKD: scientific discovery and explanation, and the evaluation of interventions.

Authors:  Francesco Locatelli; Carmine Zoccali
Journal:  Nephrol Dial Transplant       Date:  2015-08-01       Impact factor: 5.992

Review 2.  Time to re-evaluate effects of renin-angiotensin system inhibitors on renal and cardiovascular outcomes in diabetic nephropathy.

Authors:  Hiromichi Suzuki; Tomohiro Kikuta; Tsutomu Inoue; Ukihiro Hamada
Journal:  World J Nephrol       Date:  2015-02-06

3.  Impact of AKI on Urinary Protein Excretion: Analysis of Two Prospective Cohorts.

Authors:  Chi-Yuan Hsu; Raymond K Hsu; Kathleen D Liu; Jingrong Yang; Amanda Anderson; Jing Chen; Vernon M Chinchilli; Harold I Feldman; Amit X Garg; Lee Hamm; Jonathan Himmelfarb; James S Kaufman; John W Kusek; Chirag R Parikh; Ana C Ricardo; Sylvia E Rosas; Georges Saab; Daohang Sha; Edward D Siew; James Sondheimer; Jonathan J Taliercio; Wei Yang; Alan S Go
Journal:  J Am Soc Nephrol       Date:  2019-06-24       Impact factor: 10.121

4.  APOL1 risk variants, race, and progression of chronic kidney disease.

Authors:  Afshin Parsa; W H Linda Kao; Dawei Xie; Brad C Astor; Man Li; Chi-yuan Hsu; Harold I Feldman; Rulan S Parekh; John W Kusek; Tom H Greene; Jeffrey C Fink; Amanda H Anderson; Michael J Choi; Jackson T Wright; James P Lash; Barry I Freedman; Akinlolu Ojo; Cheryl A Winkler; Dominic S Raj; Jeffrey B Kopp; Jiang He; Nancy G Jensvold; Kaixiang Tao; Michael S Lipkowitz; Lawrence J Appel
Journal:  N Engl J Med       Date:  2013-11-09       Impact factor: 91.245

5.  Treatment of rheumatoid arthritis with biologic agents lowers the risk of incident chronic kidney disease.

Authors:  Keiichi Sumida; Miklos Z Molnar; Praveen K Potukuchi; Fatima Hassan; Fridtjof Thomas; Kunihiro Yamagata; Kamyar Kalantar-Zadeh; Csaba P Kovesdy
Journal:  Kidney Int       Date:  2018-03-02       Impact factor: 10.612

6.  Patterns of Kidney Function Decline in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Analysis From the HALT-PKD Trials.

Authors:  Godela M Brosnahan; Kaleab Z Abebe; Charity G Moore; Frederic F Rahbari-Oskoui; Kyongtae T Bae; Jared J Grantham; Robert W Schrier; William E Braun; Arlene B Chapman; Michael F Flessner; Peter C Harris; Marie C Hogan; Ronald D Perrone; Dana C Miskulin; Theodore I Steinman; Vicente E Torres
Journal:  Am J Kidney Dis       Date:  2018-01-03       Impact factor: 8.860

Review 7.  Epidemiology of dyslipidemia in chronic kidney disease.

Authors:  Kunitoshi Iseki
Journal:  Clin Exp Nephrol       Date:  2014-01-11       Impact factor: 2.801

8.  Association of BP variability with mortality among African Americans with CKD.

Authors:  Ciaran J McMullan; George L Bakris; Robert A Phillips; John P Forman
Journal:  Clin J Am Soc Nephrol       Date:  2013-03-14       Impact factor: 8.237

Review 9.  High serum creatinine nonlinearity: a renal vital sign?

Authors:  Carlos E Palant; Lakhmir S Chawla; Charles Faselis; Ping Li; Thomas L Pallone; Paul L Kimmel; Richard L Amdur
Journal:  Am J Physiol Renal Physiol       Date:  2016-05-18

10.  Mineral metabolites and CKD progression in African Americans.

Authors:  Julia J Scialla; Brad C Astor; Tamara Isakova; Huiliang Xie; Lawrence J Appel; Myles Wolf
Journal:  J Am Soc Nephrol       Date:  2012-12-14       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.